#PRESS: The Committee for Medicinal Products for Human Use (CHMP) has recommended approval of our GLP-1 pill for the treatment of obesity in the European Union (EU), making it one step closer to becoming available for people with overweight or obesity in the EU
[ 3 ] Variations in species studied, routes of administration, dosing regimens, and experimental methodologies likely contributed to these conflicting results
"AstraZeneca has impressive global capabilities in clinical development and commercialization
Sex differences in cancer susceptibility have been reported in some studies, although consistent evidence of different effects in men and women appears to be lacking
Meanwhile, they reported that GLP-1 receptors were expressed differently in non-neoplastic thyroid tissues according to different inflammatory states
found exendin-4 increased the expression of BDNF in mouse neocortex (178)